Prescription GLP-1 receptor agonists like semaglutide became mainstream weight loss tools after clinical trials showed average body weight reductions of 15-20%
This has the potential to modulate downstream signalling by directing the ligand towards GLP-1Rs situated in sub-microscopic membrane domains variably enriched with signalling effectors on the cytoplasmic side (Villar et al ., 2016)
Were seeing strong words come out of the Agency and a multitude of warning letters being issued to firms, including telemarketers, 503B compounders, and 503A compounders, for quality, efficacy, and advertising issues relating to compounded products
Then theres semaglutide, the GLP-1 drug behind Ozempic and Wegovy, which works in an entirely different way to support weight loss: it dials down appetite, stabilizes blood sugar, and shifts the body into fat-burning mode
Compounded medications have not been evaluated by the FDA for safety, effectiveness, or quality
&srotate=0)
